Highlights Kineta, Inc.

Equities

KA

US49461C1027

Real-time Estimate Cboe BZX Other stock markets 07:48:47 18/06/2024 pm IST			5-day change	1st Jan Change
0.494 ^USD	-8.52%		+5.87%	-86.78%

15/05	Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/04	Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	09/04	CI
Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M	22/03	MT
Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123	12/03	CI
Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity	17/01	CI
Kineta, Inc. Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer?s 38th Annual Meeting	06/11	CI
Kineta, Inc. Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Advanced Solid Tumors	17/23/17	CI
Kineta, Inc. Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 Vista-101 Clinical Trial	03/23/03	CI
Earnings Flash (KA) KINETA Posts Q2 Revenue $5.2M	12/23/12	MT
Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Earnings Flash (KA) KINETA Posts Q1 Revenue $281,000	12/23/12	MT
Kineta, Inc. Unveils New Vista Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update At AACR Annual Meeting 2023	17/23/17	CI
Kineta, Inc. completed the acquisition of Yumanity Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	16/22/16	CI
Kineta, Inc. entered into definitive agreement to acquire Yumanity Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	06/22/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer